NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Support for cancer research projects seeking breakthroughs in diagnosis, treatment, and prevention, with potential for major impact on clinical and preclinical fields.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 13, 2025 | March 1, 2025 (AIDS) | June 12, 2025 | July 1, 2025 (AIDS)
Funding Amounts: Up to $275,000 direct costs over 2 years (no more than $200,000 in any single year); project period max 2 years.
Summary: Supports high-risk, early-stage exploratory and developmental research in cancer diagnosis, treatment, prevention, and related clinical/preclinical studies.
Key Information: Applications focused on basic cancer biology, late-stage clinical trials, or epidemiology are not eligible; clinical trial optional.
Description
This opportunity from the National Cancer Institute (NCI) supports innovative, hypothesis-driven exploratory and developmental research projects (R21 mechanism) in cancer. The focus is on preclinical and early phase clinical studies, correlative studies, and projects that could lead to breakthroughs in cancer diagnosis, treatment, prevention, imaging, symptom/toxicity management, and reduction of cancer disparities. The program encourages high-risk, high-reward research that may lead to the development of novel agents, methodologies, models, or applications with significant impact on cancer research or clinical practice.
Projects may include:
- Early-phase clinical trials of new or repurposed agents, combinations, or interventions (including radiation).
- Development and validation of predictive/prognostic biomarkers or imaging tools.
- Preclinical studies using clinically relevant models (e.g., organoids, patient-derived xenografts).
- Comparative oncology studies (including in dogs as models for human disease).
- Research addressing cancer health disparities.
Note: Applications focused on basic cancer biology (e.g., studies of molecular mechanisms, pathways, or tumor microenvironment not directly tied to clinical/preclinical development), late-stage clinical trials, epidemiological, or behavioral intervention studies are not responsive and will not be reviewed.
